论文信息 - A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4. - 字舞流文

A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.

M. Glennie | C. Ottensmeier | Anthony P. Williams | N. Steven | Peter W. M. Johnson | M. Ashton-Key | E. Hodges | F. Chowdhury | E. Hall | J. Dobbyn